Silvercrest Asset Management Group LLC Purchases 273,838 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Silvercrest Asset Management Group LLC grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 39.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 973,888 shares of the medical equipment provider's stock after buying an additional 273,838 shares during the period. Silvercrest Asset Management Group LLC owned 1.40% of Lantheus worth $87,124,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Kestra Investment Management LLC acquired a new stake in Lantheus during the 4th quarter worth about $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus during the 4th quarter valued at about $37,000. UMB Bank n.a. boosted its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. bought a new stake in Lantheus in the fourth quarter worth approximately $125,000. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $132.67.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 over the last 90 days. Corporate insiders own 1.50% of the company's stock.

Lantheus Trading Down 1.3%

Shares of LNTH stock traded down $0.96 during trading hours on Wednesday, hitting $75.87. 452,917 shares of the company's stock were exchanged, compared to its average volume of 981,922. The company has a market capitalization of $5.25 billion, a PE ratio of 12.66 and a beta of 0.23. The business's 50 day simple moving average is $96.20 and its 200-day simple moving average is $92.76. Lantheus Holdings, Inc. has a 12-month low of $75.00 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the prior year, the firm earned $1.69 EPS. The firm's revenue for the quarter was up .8% on a year-over-year basis. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.